BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11039581)

  • 1. Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family.
    Ginjaar IB; Kneppers AL; v d Meulen JD; Anderson LV; Bremmer-Bout M; van Deutekom JC; Weegenaar J; den Dunnen JT; Bakker E
    Eur J Hum Genet; 2000 Oct; 8(10):793-6. PubMed ID: 11039581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy.
    Shiga N; Takeshima Y; Sakamoto H; Inoue K; Yokota Y; Yokoyama M; Matsuo M
    J Clin Invest; 1997 Nov; 100(9):2204-10. PubMed ID: 9410897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of Becker muscular dystrophy resulting from the skipping of four contiguous exons (71-74) of the dystrophin gene during mRNA maturation.
    Patria SY; Alimsardjono H; Nishio H; Takeshima Y; Nakamura H; Matsuo M
    Proc Assoc Am Physicians; 1996 Jul; 108(4):308-14. PubMed ID: 8863344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.
    Disset A; Bourgeois CF; Benmalek N; Claustres M; Stevenin J; Tuffery-Giraud S
    Hum Mol Genet; 2006 Mar; 15(6):999-1013. PubMed ID: 16461336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insertion of a 5' truncated L1 element into the 3' end of exon 44 of the dystrophin gene resulted in skipping of the exon during splicing in a case of Duchenne muscular dystrophy.
    Narita N; Nishio H; Kitoh Y; Ishikawa Y; Ishikawa Y; Minami R; Nakamura H; Matsuo M
    J Clin Invest; 1993 May; 91(5):1862-7. PubMed ID: 8387534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
    Takeshima Y; Yagi M; Wada H; Matsuo M
    Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two distinct mutations in a single dystrophin gene: identification of an altered splice-site as the primary Becker muscular dystrophy mutation.
    Wilton SD; Johnsen RD; Pedretti JR; Laing NG
    Am J Med Genet; 1993 Jun; 46(5):563-9. PubMed ID: 8322822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophin nonsense mutations can generate alternative rescue transcripts in lymphocytes.
    Nishiyama A; Takeshima Y; Zhang Z; Habara Y; Tran TH; Yagi M; Matsuo M
    Ann Hum Genet; 2008 Nov; 72(Pt 6):717-24. PubMed ID: 18652600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of dystrophin mRNA from skeletal muscle but not from lymphocytes led to identification of a novel nonsense mutation in a carrier of Duchenne muscular dystrophy.
    Ito T; Takeshima Y; Yagi M; Kamei S; Wada H; Nakamura H; Matsuo M
    J Neurol; 2003 May; 250(5):581-7. PubMed ID: 12736738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a point mutation and germinal mosaicism in a Duchenne muscular dystrophy family.
    Wilton SD; Chandler DC; Kakulas BA; Laing NG
    Hum Mutat; 1994; 3(2):133-40. PubMed ID: 8199594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.
    Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB
    Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
    Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
    Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
    J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular genetics and problems found in genetic diagnosis of Duchenne Becker muscular dystrophy].
    Takeshima Y; Matsuo M
    Nihon Rinsho; 1997 Dec; 55(12):3120-5. PubMed ID: 9436421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced dystrophin exon skipping in human muscle explants.
    McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
    Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutations in Czech DMD/BMD patients and their phenotypic outcome.
    Sedlácková J; Vondrácek P; Hermanová M; Zámecník J; Hrubá Z; Haberlová J; Kraus J; Maríková T; Hedvicáková P; Vohánka S; Fajkusová L
    Neuromuscul Disord; 2009 Nov; 19(11):749-53. PubMed ID: 19783145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene.
    Deburgrave N; Daoud F; Llense S; Barbot JC; Récan D; Peccate C; Burghes AH; Béroud C; Garcia L; Kaplan JC; Chelly J; Leturcq F
    Hum Mutat; 2007 Feb; 28(2):183-95. PubMed ID: 17041906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.